Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
2016
2015
HAI/WHO Pharmaceutical Promotion Manual Still Key to Combating Promotion around the World
It’s Time Everyone Knows about Price Inequities in Insulin
HAI Holds Workshops on EU Medicines Policy & Access to Medicines in Eastern Europe
HAI urges MEPs to support key amendments to TTIP resolution
The EU-US Trade Deal Could Leave Europeans Sick
World Health Assembly Executive Board 136: YP-CDN, NWIA and HAI intervention on the WHO’s internship programme
HAI Launches Innovative Global Study to Improve Access to Insulin
In memory of our Foundation Board Chair, Atze Sybrandy
2014
Student Stop AIDS National Gathering an inspiring start to Access to Medicines Week
Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry
Democracy violation: European Commission rejects citizens’ initiative to stop TTIP and CETA
School's IN for summer: HAI staff and interns inspired by Utrecht University's course on pharmaceutical policy analysis
BMJ statins debate about scientific independence, not rigour
Progress on access to medicines at WHA67, but WHO funding sorely needed
World Health Assembly 67: HAI and KEI intervention on the Consultative Expert Working Group on Research and Development
World Health Assembly 67: HAI intervention on access to essential medicines
World Health Assembly 67: HAI intervention on the WHO's framework of engagement with non-state actors
Tamiflu review shows desperate need for full clinical trials data transparency
Governments must ensure Big Pharma’s expansion in Africa doesn’t impede generics supply
New materials help assess medicines policies and interventions
A new (and improved) model to regulate pharmaceutical promotion
Enhancing accountability in the medicines market: The Medicines Transparency Alliance
Bayer CEO's callous comments highlight failure of current biomedical innovation model
2013
When politicians go to the movies
2011
DG Trade State of Play reveals EU's ambitions for IP protection in FTAs
2010